Cinthi Marzia, Coccitto Sonia Nina, Pocognoli Antonella, Zeni Guido, Mazzariol Annarita, Di Gregorio Alessandra, Vignaroli Carla, Brenciani Andrea, Giovanetti Eleonora
Department of Life and Environmental Sciences, Polytechnic University of Marche, Ancona, Italy.
Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
J Glob Antimicrob Resist. 2024 Mar;36:358-364. doi: 10.1016/j.jgar.2024.01.020. Epub 2024 Feb 7.
Staphylococcus epidermidis is a member of the human skin microbiome. However, in recent decades, multidrug-resistant and hospital-adapted S. epidermidis clones are increasingly involved in severe human infections associated with medical devices and in immunocompromised patients. In 2016, we reported that a linezolid- and methicillin-resistant S. epidermidis ST2 clone, bearing the G2576T mutation, was endemic in an Italian hospital since 2004. This study aimed to retrospectively analyse 34 linezolid- and methicillin-resistant S. epidermidis (LR-MRSE) strains collected from 2018 to 2021 from the same hospital.
LR-MRSE were typed by Pulsed-Field Gel Electrophoresis and multilocus sequence typing and screened for transferable linezolid resistance genes. Representative LR-MRSE were subjected to whole-genome sequencing (WGS) and their resistomes, including the presence of ribosomal mechanisms of linezolid resistance and of rpoB gene mutations conferring rifampin resistance, were investigated.
ST2 lineage was still prevalent (19/34; 55.9%), but, over time, ST5 clone has been widespread too (15/34; 44.1%). Thirteen of the 34 isolates (38.2%) were positive for the cfr gene. Whole-genome sequencing analysis of relevant LR-MRSE displayed complex resistomes for the presence of several acquired antibiotic resistance genes, including the SCCmec type III (3A) and SCCmec type IV (2B) in ST2 and ST5 isolates, respectively. Bioinformatics and polymerase chain reaction (PCR) mapping also showed a plasmid-location of the cfr gene and the occurrence of previously undetected mutations in L3 (ST2 lineage) and L4 (ST3 lineage) ribosomal proteins and substitutions in the rpoB gene.
The occurrence of LR-MRSE should be carefully monitored in order to prevent the spread of this difficult-to-treat pathogen and to preserve the efficacy of linezolid.
表皮葡萄球菌是人体皮肤微生物群的成员。然而,在最近几十年中,多重耐药且适应医院环境的表皮葡萄球菌克隆越来越多地涉及与医疗器械相关的严重人类感染以及免疫功能低下的患者。2016年,我们报告称,自2004年以来,携带G2576T突变的耐利奈唑胺和耐甲氧西林表皮葡萄球菌ST2克隆在一家意大利医院呈地方性流行。本研究旨在回顾性分析2018年至2021年从同一家医院收集的34株耐利奈唑胺和耐甲氧西林表皮葡萄球菌(LR-MRSE)菌株。
采用脉冲场凝胶电泳和多位点序列分型对LR-MRSE进行分型,并筛选可转移的利奈唑胺耐药基因。对代表性的LR-MRSE进行全基因组测序(WGS),并研究其耐药组,包括利奈唑胺耐药的核糖体机制以及赋予利福平耐药性的rpoB基因突变的存在情况。
ST2谱系仍然占主导地位(19/34;55.9%),但随着时间的推移,ST5克隆也广泛传播(15/34;4-4.1%)。34株分离株中有13株(38.2%)cfr基因呈阳性。对相关LR-MRSE的全基因组测序分析显示,由于存在多个获得性抗生素耐药基因,其耐药组较为复杂,包括ST2和ST5分离株中分别存在的III型(3A)和IV型(2B)SCCmec。生物信息学和聚合酶链反应(PCR)图谱分析还显示了cfr基因的质粒定位,以及L3(ST2谱系)和L4(ST3谱系)核糖体蛋白中先前未检测到的突变的发生以及rpoB基因中的替代。
应密切监测LR-MRSE的发生情况,以防止这种难以治疗的病原体传播,并保持利奈唑胺的疗效。